None listed
Conditions
Interventions
None listed
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults over 18 years of age 2. Patients diagnosed with polycythemia vera according to the World Health Organization (WHO) criteria 3. Patients who are currently being treated with ropeginterferon after receiving at least one prescription, or who are scheduled to receive Ropeginterferon 4. Patients confirmed to have the JAK2 V617F mutation 5. Patients who have received sufficient explanation about participation in the study and voluntarily signed the Informed Consent Form (ICF)
Exclusion criteria
Exclusion criteria: 1. Patients who, in the investigator’s clinical judgment, are expected to have difficulty with follow-up or with completing study procedures 2. Patients who are deemed unsuitable for study participation due to significant comorbidities or other reasons 3. Patients for whom blood testing or blood sampling is medically contraindicated 4. Patients who discontinued Ropeginterferon more than 6 months prior and have no plan for re-administration 5. Patients with contraindications or hypersensitivity to Ropeginterferon
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in JAK2 V617F allele burden;Achievement of Molecular Response (MR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Event-Free Survival(EFS);Time to MR;Achievement of Complete Hematologic Response (CHR);Time to CHR;Identification of clinical predictors of CHR and MR;Correlation between CHR and MR | — |
Countries
Korea, Republic of
Contacts
Public ContactSung-Eun Lee
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed